Earlier this month, the FDA approved the drug remdesivir to treat patients hospitalized with COVID-19. Shipments of remdesivir began going out last week, but only 607,000 of the 1,500,000 vials that drugmaker Gilead is donating are being distributed in the US. There are over 300,000 patients eligible to receive remdesivir in the US, but the …
Clinical studies involving remdesivir as a treatment for the coronavirus has yielded encouraging results. Remdesivir was developed by Gilead as a drug to treat Ebola patients, but the FDA approved it as a coronavirus treatment late last week. Gilead CEO Daniel O’Day said that remdesivir will be used on coronavirus patients starting next week. O’Day …
A National Institutes of Health (NIH) trial involving more than 1,000 patients revealed that remdesivir can help COVID-19 patients recover faster. Dr. Anthony Fauci said that the drug will become the standard of care for the novel coronavirus disease. The study hasn’t been published or peer-reviewed and some questions still remain, but the early results …
Two studies focusing on the most promising coronavirus drugs just delivered bad news about the COVID-19 treatments. An observational hydroxychloroquine study from New York revealed the drug failed to show any promise on COVID-19 patients experiencing severe symptoms. In addition, a randomized remdesivir clinical trial from China revealed the drug had no effect on patients …
A promising coronavirus drug that’s been in testing around the world for months is showing promise at treating COVID-19 severe cases. Remdesivir is the medicine in question, an anti-viral originally created to treat Ebola. Anecdotal evidence shows that the drug can reduce fever and need for ventilation, and can significantly improve the condition of severe …
